Companies › BBIO

BRIDGEBIO PHARMA INC (BBIO)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001743881 · EDGAR filings · Updated 2026-07-27

BRIDGEBIO PHARMA INC (BBIO) has reported institutional ownership of 99.4%, with 457 institutional managers holding positions valued at $14.4B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Filings this week (4)

• 2026-07-27 — SCHEDULE 13G/A filed
• 2026-07-24 — S-3ASR filed
• 2026-07-24 — Employee-plan registration (S-8) filed
• 2026-07-22 — Current report (8-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-13 — Insider transaction reported (Form 4)
• 2026-07-13 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, BRIDGEBIO PHARMA INC has 457 institutional holders and institutional ownership of 99.4%.

Insider activity

Insiders reported 208 transactions (3 buys, 151 sells) across 18 reporting insiders, with a net reported value of −$483.5M.

Data flags from SEC filings

Related companies

ROIVANT SCIENCES LTD (ROIV) · COOPER COS INC (COO) · INSULET CORP (PODD) · VIATRIS INC (VTRS) · NEUROCRINE BIOSCIENCES INC (NBIX) · ELANCO ANIMAL HEALTH INC (ELAN)